脉血康胶囊治疗脑梗死的临床研究

目的观察脉血康胶囊治疗脑梗死的临床疗效及不良反应。方法将180例脑梗死病人随机分为两组,试验组100例,口服脉血康胶囊3粒,每日3次;对照组80例,口服通塞脉胶囊3粒,每日3次,两组疗程均4周。结果试验组的总有效率为90.0%,对照组的总有效率为86.3%,两组比较差异无统计学意义(P>0.05)。4周治疗过程中,总计不良事件发生率在试验组和对照组分别为5.1%和5.8%。结论脉血康胶囊治疗脑梗死疗效较好且安全。

Treatment of Cerebral Infarction by Maixuekang Capsule

Objective To observe the clinical therapeutic effect and adverse effect of Maixuekang capsule for cerebral infarction.Methods One hundred and eighty patients (pts) were divided into Maixuekang group (n=100) and Tongsaimai group (n=80). Results The effective rate was no differences pre- and post-treatment in both groups(P>0.05). The improvement rate was 90.0%in Maixuekang group and 86.3% in Tongsaimai group(P>0.05). The excellence rate was different significantly in both groups(P<0.05). The rate of adverse events in Maixuekang group and Tongsaimai group was 5.1% and 5.8% respectively. Conclusion Maixuekang capsule was effective and safe for cerebral infarction.